Characterization Of Liver Lesions Research Articles

1088: Contrast-enhanced sonography for characterization of focal liver lesions: Reliability and cost-effectiveness

The efficacy of contrast-enhanced sonography for characterizing focal liver lesions has been demonstrated in many reports of literature and validated in the Guidelines for the Use of Ultrasound Contrast Agents of the European Federation of Ultrasound Societies (EFSUMB). In our five-y experience, in 686 patients 694 focal liver lesions initially detected by US underwent CEUS, performed in continuous mode, with low mechanical index and contrast-specific software (CPS, Acuson-Siemens, and CnTI, Esaote) after bolus administration of 2.4 ml of SonoVue (Bracco, Milan, Italy).

Contrast enhanced ultrasonography in characterization of focal liver lesions in cirrhosis: A prospective study of 96 patients

Contrast enhanced ultrasonography in characterization of focal liver lesions in cirrhosis: A prospective study of 96 patients

Gradient‐ and spin‐echo T2‐weighted imaging for SPIO‐enhanced detection and characterization of focal liver lesions

To evaluate superparamagnetic iron oxide (SPIO)-enhanced breathhold T2-weighted GRASE imaging in detection and characterization of focal liver lesions. In 30 patients (including 20 with cirrhosis) with 39 malignant and 25 benign lesions, gradient- and spin-echo (GRASE) images with two echo times (75 and 90 msec; GRASE75 and GRASE90) were obtained prior to and following administration of SPIO, and compared with respiratory-triggered and breathhold fast spin-echo (RT-FSE and BH-FSE) images. Two readers evaluated image quality and reviewed 240 liver segments for sensitivity and specificity. Signal-to-noise ratio (SNR), and its reduction in liver and spleen after administration of SPIO, and lesion-to-liver contrast-to-noise ratio (CNR) were measured. Compared with RT-FSE and BH-FSE, GRASE reduced scan time by 77% to 82% and 21% to 27%, respectively. The image qualities with BH-FSE and GRASE75 were higher than with BH-FSE and GRASE90. BH-FSE showed higher specificity than RT-FSE and GRASE90, but otherwise there were no significant differences between pulse sequences for sensitivity or specificity. The mean SNR and CNR of the lesions with RT-FSE were significantly higher than with the other methods. SPIO-induced signal reduction of liver SNR was smallest with BH-FSE. GRASE is faster and more sensitive to SPIO than FSE, but its sensitivity and specificity were slightly inferior to those of BH-FSE. Image quality is a current limitation.

Focal liver lesions: Breathhold gradient‐ and spin‐echo T2‐weighted imaging for detection and characterization

To evaluate breathhold gradient- and spin-echo (GRASE) T2-weighted imaging for the detection and characterization of focal liver lesions. Two GRASE sequences with different echo times (75 and 90 msec, GRASE75 and GRASE90) were compared with respiratory-triggered fast spin-echo (SE) and breathhold fast SE in 64 patients with 103 malignant and 51 benign lesions. Compared with respiratory-triggered and breathhold fast SE, GRASE reduced scan time by 77% to 82% and 21% to 27%, respectively. Two independent readers evaluated image quality and reviewed 504 liver segments on a segment-by-segment basis. Observer performance was evaluated with receiver operating characteristic (ROC) curve analysis. The signal-to-noise ratio (SNR) of liver and spleen, and lesion-to-liver contrast-to-noise ratio (CNR) were also measured. The overall quality of the GRASE images was higher than that of the respiratory-triggered and breathhold fast SE images, although signal inhomogeneities were more frequently observed with GRASE. No significant difference in the values of the area under the ROC curve (Az) for malignant lesion detection was found. The mean SNR and CNR were highest for respiratory-triggered fast SE. T2-weighted breathhold GRASE has the potential to provide faster liver imaging.

Characterization of Small Focal Liver Lesions Using Real‐time Contrast‐Enhanced Sonography

The purpose of this study was to assess the diagnostic performance of real-time contrast-enhanced sonography in characterization of small focal liver lesions (FLLs; < or = 3.0 cm in diameter). Two hundred small FLLs in 200 patients were examined by contrast-enhanced sonography using a contrast-specific mode of contrast pulse sequencing and a sulfur hexafluoride-filled microbubble contrast agent. The sonographic images were reviewed by 2 independent readers. A 5-point confidence level was used to discriminate malignant from benign FLLs, and specific diagnoses were recorded. The diagnostic performances were evaluated by receiver operating characteristic (ROC) analysis, and the interobserver agreement was analyzed by weighted kappa statistics. After review of contrast-enhanced sonography, ROC analysis revealed significant improvement in differentiating between malignant and benign small FLLs that the areas under the ROC curve were 0.856 at baseline sonography versus 0.954 at contrast-enhanced sonography for reader 1 (P < .001) and 0.857 versus 0.954 for reader 2 (P = .003). The sensitivity, negative predictive value, and accuracy for both readers also improved significantly after contrast agent administration (all P < .001). A better result of specific diagnosis was obtained (38.5% [77/200] at baseline sonography versus 80.5% [161/200] at contrast-enhanced sonography for reader 1 and 34.5% [69/200] versus 80.5% [161/200] for reader 2; both P < .001) after contrast agent administration, and a better interobserver agreement was achieved (kappa = 0.425 at baseline sonography versus 0.716 at contrast-enhanced sonography). Real-time contrast-enhanced sonography improves the diagnostic performance in small FLLs compared with baseline sonography.

Impact of European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) guidelines on the use of contrast agents in liver ultrasound

The introduction of microbubble contrast agents and the development of contrast-specific techniques have opened new prospects in liver ultrasound. Over the past few years several reports have shown that contrast ultrasound can substantially improve detection and characterization of focal liver lesions with respect to baseline studies. The advent of second-generation agents and low mechanical index real-time scanning techniques has been instrumental in improving the easiness and the reproducibility of the examination. With the publication of the guidelines for the use of contrast agents in liver ultrasound by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB), contrast ultrasound enters into clinical practice. The guidelines define the indications and recommendations for the use of contrast ultrasound in focal liver lesion detection, characterization, and follow-up after tumor ablation procedures. We discuss the impact of EFSUMB guidelines on diagnostic protocols currently adopted in liver imaging.

Diagnostic Accuracy of Contrast-Enhanced Ultrasound in Focal Lesions of the Liver Using Cadence Contrast Pulse Sequencing

The purpose of this study was to assess the accuracy of Cadence Contrast Pulse Sequencing (Siemens-Acuson, CA) method with injection of SonoVue (Bracco Imaging SpA, Italy) for the detection and characterisation of focal liver lesions in comparison with a reference modality during routine use. 138 consecutive patients (62 women, 76 men; mean age: 52 years for women and 63 years for men) corresponding to 144 examinations with 381 lesions participated in this prospective study from December 2002 to November 2003. Inclusion criteria were lesions detected by conventional US and the availability of a reference imaging examination (CT or MR imaging) within three weeks. The underlying liver lesions characterised by a reference modality (including biopsy in 29 lesions) were distributed as follows: haemangioma (n = 56), focal nodular hyperplasia (n = 27), hepatocellular carcinoma (n = 44), hepatocellular adenoma (n = 5), liver metastasis (n = 174), abscess (n = 2), cysts (n = 45), other benign lesions (n = 24) and 3 peritoneal metastases. A significant improvement was reported in the number of detected lesions between contrast-enhanced ultrasound and baseline ultrasonography (351 lesions versus 280 lesions, respectively, p < 0.01), whereas no significant difference was noted between contrast-enhanced ultrasound and reference imaging (351 versus 377 lesions, respectively). On the whole, contrast-enhanced ultrasound allowed a complete diagnosis in 96 % of the detected nodules with a significant improvement compared to conventional sonography in which the diagnosis was suspected in only 52 % out of these cases (p < 0.001). No significant difference was noted between contrast-enhanced ultrasound and the reference modality concerning characterisation of nodules. The present study clearly indicates that contrast-enhanced sonography using Sonovue and Cadence Contrast Pulse Sequencing allows real-time imaging with high accuracy and thus will be a competitive alternative to other modalities such as CT and MR imaging for liver imaging.

Characterization of focal liver lesions using contrast-enhanced sonography with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent

To characterize focal liver lesions (FLLs) using real-time contrast-enhancedsonography (CEUS) with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent. CEUS was performed in 190 patients with FLLs, including hepatocellular carcinoma (HCC) (n = 107), liver metastasis (n = 21), intrahepatic cholangiocarcinoma (ICC) (n = 7), liver hemangioma (n = 37), focal nodular hyperplasia (FNH) (n = 11), regenerative nodule (n = 6) and liver lipoma (n = 1). The cadence contrast pulse sequencing technique and the contrast agent SonoVue(R) were used for CEUS examination. The enhancement patterns during the arterial, portal, and late phases were evaluated. HCC showed hyperenhancement in 100 (93.5%) of 107 nodules during the arterial phase and hypoenhancement in 102 (95.3%) during the late phase. Liver metastases showed homogeneous enhancement in 8 of 21 (38.1%) nodules and a peripheral regular rim-like enhancement in 11 of 21 (52.4%) nodules during the arterial phase and marked hypoenhancement in 16 of 21 (76.2%) nodules during the late phase. ICC exhibited irregular rim-like enhancement in 4 of 7 (57.1%) nodules during the arterial phase and hypo-enhancement in 7 of 7 (100%) nodules during the late phase. Hemangioma showed peripheral nodular hyperenhancement, and progressive centripetal enhancement was seen in 35 of 37 (94.6%) lesions during the arterial phase. All 11 cases of FNH exhibited homogeneous hyperenhancement during the arterial phase and hyperenhancement (n = 1) or isoenhancement (n = 9) during the late phase. The sensitivity, specificity, and positive predictive value, respectively, were 88.8%, 89.2%, and 91.3% for HCC; 81%, 100%, and 100% for liver metastasis; 57.1%, 100%, and 100% for ICC; 94.6%, 100%, and 100% for liver hemangioma; and 90.9%, 97.8%, and 71.4% for FNH. Low-mechanical index CEUS permits real-time, complete assessment of vascularity in FLLs, which in turn facilitates their characterization.

European federation of societies for ultrasound in medicine and biology (EFSUMB) guidelines for the use of contrast agents in liver ultrasound: what is the impact in clinical practice?

Ultrasound is the most commonly used liver imaging modality worldwide. Unfortunately, ultrasound has limited sensitivity in the detection of small tumour nodules. Moreover, ultrasound findings are often non-specific, as there is enough variability and overlap in the appearance of benign and malignant liver lesions to make a definite distinction problematic. Recently, the introduction of microbubble contrast agents and the development of contrast-specific techniques have opened new prospects in liver ultrasound. The advent of second-generation agents that have higher harmonic emission capabilities has been instrumental in improving the easiness and the reproducibility of the examination. Over the past few years, several reports have shown that real-time contrast-enhanced ultrasound can substantially improve detection and characterization of focal liver lesions with respect to baseline studies. With the publication of the guidelines for the use of contrast agents in liver ultrasound by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB), contrast-enhanced ultrasound has entered clinical practice. The guidelines define the indications and recommendations for the use of contrast agents in focal liver lesion detection, characterization and posttreatment follow-up. In this paper, we discuss the impact of EFSUMB guidelines on diagnostic protocols currently adopted in liver imaging with regard to four clinical scenarios: (1) characterization of focal liver lesions of incidental detection; (2) diagnosis of HCC in patients with cirrhosis; (3) detection of hepatic metastases in oncology patients; (4) guidance and assessment of the outcome of percutaneous tumour ablation procedures.

Adverse Effects Associated with SonoVue Use

AbstractFor Abstract see ChemInform Abstract in Full Text.

Characterization of focal liver lesions using an innovative contrast-enhanced ultrasound technique

To evaluate the clinical performance of an innovative contrast-enhanced ultrasound (CEUS) technique in characterization of focal liver lesions (FLL). CEUS was performed in 505 patients with FLLs. A sulfur hexafluoride-filled microbubble ultrasound contrast agent and a continuous real-time imaging technique of contrast pulse sequencing were used. The observation items included initial nodule enhancement time, enhancement level and pattern, and dynamic evolution of enhancement along with the CEUS phases. There were similar findings for both malignant and benign FLLs in initial enhancement time and enhancement level on CEUS. The dynamic evolution of enhancement along with enhancement phase was the most significant parameter for characterization of FLLs. Most malignant lesions showed enhancement at arterial phase and hypo-enhancing at late phase, whereas the benign lesions presented enhancement at arterial phase and persistent hyper- or iso-enhancing until late phase. Using these characteristics as a diagnostic criteria, the sensitivity, specificity, positive predicative value, negative predicative value and accuracy of CEUS in identifying malignant FLLs were 95.7% (313/327), 86.0% (153/178), 92.6% (313/338), 91.6% (153/167) and 92.3% (466/505), respectively. Characterization of FLLs by using the innovative CEUS technique is recommendable due to its safety, facility and high accuracy.

Ultraschallkontrastmittel - Grundlagen und klinische Anwendung

This article reviews the technical basics and the application of contrast-enhanced ultrasonography. Ultrasound contrast agents have been evaluated in various organs and have proven to be particularly useful in the detection and characterization of liver lesions. Experiences in small parts (such as breast, or lymph nodes) are so far limited, because only since recently are the technical prerequisites available for contrast-enhanced ultrasound high-frequency transducers. Ultrasound contrast media can be used for functional studies, e. g., of organ or tumor perfusion. Mathematical models were primarily developed for measuring myocardial perfusion and have recently been adapted for studying tumors. In animal experiments as well as in clinical applications, quantitative parameters of tumor perfusion have been evaluated as surrogate parameters for response to radiotherapy, chemotherapy, or treatment with anti-angiogenic agents.

Focal lesions in normal liver

A variety of lesions occur in the normal liver. This review will describe the most common benign, malignant, and infectious lesions. Illustration will be made of the magnetic resonance imaging (MRI) appearance of the most common of these. Due to the high accuracy for liver lesion detection and characterization, and the intrinsic safety of the modality, MR should be considered the primary imaging tool to investigate liver diseases.

Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound

Non-invasive differentiation of focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) is difficult. The aim of this study was to assess the accuracy of contrast-enhanced phase inversion ultrasound to differentiate between histologically proven FNH and HCA, analysing the arterial and (early) portal venous phase. 32 patients with histological proven FNH (n=24) or HCA (n=8) have been included in this prospective study. Examination technique: Siemens Elegra, phase inversion harmonic imaging (PIHI) with low mechanical index (MI)<0.2-0.3 using SonoVue (BR 1). The contrast enhancing tumour characteristics were evaluated during the hepatic arterial (starting 8-22 s) and early portal venous phase (starting 12-30 s). The image analysis was performed by three examiners. In 23 of 24 patients with FNH the contrast pattern revealed pronounced arterial and (early) portal venous enhancement. Homogeneous enhancement was detected during the hepatic arterial phase in all eight patients with HCA. In contrast to patients with FNH, no enhancement was seen during the portal venous phase. In conclusion, contrast-enhanced phase inversion ultrasound demonstrated pronounced arterial and portal venous enhancement in patients with focal nodular hyperplasia. In contrast, after homogeneous enhancement during hepatic arterial phase, no enhancement during hepatic portal venous phase was detected in patients with hepatocellular adenoma. Therefore, this technique might improve the functional characterization of benign hypervascular focal liver lesions.

Adverse effects associated with SonoVue® use

Conventional ultrasonography (US) has limited accuracy in the detection and characterisation of solid focal liver lesions (FLL). Contrast-enhanced ultrasound (CEUS) significantly improves the diagnostic performance of US in the assessment of FLL. Rare reports of serious adverse events have been reported with CEUS. The rates of adverse reactions reported from the use of ultrasound contrast agents seem comparable to, or lower than, those observed for other imaging modalities that use contrast agents such as computed tomography and magnetic resonance imaging. Improved diagnostic results and diagnostic confidence achieved in conventional CEUS studies of the liver and during the investigational use in the intraoperative CEUS exploration appear to justify the use of this promising modality.

251 Characterization of incidental liver lesions with contrast-enhanced ultrasound: Prospective validation of the guidelines of the european federation of societies for ultrasound in medicine and biology

251 Characterization of incidental liver lesions with contrast-enhanced ultrasound: Prospective validation of the guidelines of the european federation of societies for ultrasound in medicine and biology

258 Real time characterization of focal liver lesions using contrast-enhanced ultrasound after the injection of sonovue, a second-generation contrast agent

258 Real time characterization of focal liver lesions using contrast-enhanced ultrasound after the injection of sonovue, a second-generation contrast agent

Imaging of Focal Liver Lesions

The purpose of this study was to evaluate the usefulness of a contrast-enhanced contrast-specific ultrasonographic technique with a low mechanical index for characterization of focal liver lesions. Contrast-specific ultrasonography was used to assess 144 patients with 147 focal liver lesions: 87 primary liver carcinomas, 27 hemangiomas, 16 focal nodular hyperplasias, 5 hepatic abscesses, 3 inflammatory pseudotumors of the liver, and 9 metastases. A sulfur hexafluoride gas-based contrast agent was used with a mechanical index of 0.08 to 0.11. On contrast-enhanced ultrasonography, the typical hemodynamic pattern of primary liver carcinoma was the whole-lesion enhancement or mosaic enhancement in the arterial phase with an enhancement defect in the late phase (sensitivity, 92.0%; specificity, 86.7%). The most common enhancement pattern of hemangioma was that enhancement appeared in the periphery first and progressively filled into the lesion center (sensitivity, 96.3%; specificity, 97.5%). The enhancement pattern of focal nodular hyperplasia was that the whole lesion enhanced early and rapidly in the arterial phase with a centrifugal radiating configuration and appeared isoechoic or hyperechoic until the late phase (sensitivity, 87.6%; specificity, 94.5%). The central scar was detected in 31.3% of cases in the late phase. The specific enhancement of a hepatic abscess was the honeycomblike enhancement in all phases (sensitivity, 80.0%; specificity, 100%). No enhancement of a lesion in all phases was specific for an inflammatory pseudotumor of the liver. Contrast-enhanced real-time ultrasonography is a promising approach in the noninvasive characterization of focal liver lesions and can be useful as a first-line imaging technique clinically when a focal liver lesion is detectable on ultrasonography.

Multidetektor-CT (MDCT) der Leber

Multidetector-row CT (MDCT) scanners have dramatically improved liver imaging. With the newest generation of 40-64 row scanners, true isotropic imaging with a z-axis resolution of 0.3-0.6 mm has become possible. Acquisition time for the scan has been shortened to a few seconds. To fully exploit the advantages of MDCT scanners in liver imaging, the examination protocols have to be optimized with regard to contrast material flow rate, scan delay, and the number of scans performed. The possible advantages of double arterial phase scans in the detection of HCC are discussed. The clinical value of 3D reconstructions, such as multiplanar reconstructions and curved planar reconstructions, for assessment of the vascular and biliary duct infiltration is demonstrated. Optimized MDCT imaging improves detection and characterization of focal liver lesions.

Kontrastverst�rkte Sonographie der Leber

The detection rate of liver lesions using ultrasonography is 53-77%, rendering this method inferior to CT and MRI. Despite well-known limitations, development of stable second-generation contrast agents in conjunction with new techniques of contrast display has led to increased diagnostic accuracy. Characterization of focal liver lesions with ultrasound contrast agents follows known features of iodine- and gadolinium-containing contrast agents, but compared to CT and MRI sensitive visualization of intratumoral vessels takes place in real time. In addition to very high diagnostic accuracy in differentiating benign from malignant lesions, detectability of tumors of nonhepatocellular origin is increased significantly and direct assessment of treatment success with minimally invasive tumor ablative interventions in the liver is possible. The active principle of ultrasound contrast agents, examination technique as well as distinguishing features and appearance of various, frequently observed focal liver lesions are illustrated by cases from our department.